CX3CL1

CX3CL1

CX3CL1 Overview

Molecule Name
C-X3-C motif chemokine ligand 1
Synonyms
CX3CL1,Fractalkine
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Small Inducible Cytokine Subfamily D (Cys-X3-Cys), Member 1 (Fractalkine, Neurotactin),Small Inducible Cytokine Subfamily D (Cys-X3-Cys), Member-1,CX3CL1,Small-inducible cytokine D1,FKN,Fractalkine,A-152E5.2,C-X3-C Motif Chemokine Ligand 1,Chemokine (C-X3-C Motif) Ligand 1,CX3C Membrane-Anchored Chemokine,C-X3-C Motif Chemokine 1,Neurotactin,SCYD1,NTT,C3Xkine,ABCD-3,CXC3C,CXC3,NTN,Chemokine CX3CL1
Background
Fractalkine is also known as C-X3-C motif chemokine 1 (CX3CL1) and neurotactin. Fractalkine is a large cytokine protein of 373 amino acids, it contains multiple domains and is the only known member of the CX3C chemokine family. Fractalkine is found commonly throughout the brain, particularly in neural cells, and its receptor is known to be present on microglial cells. It has also been found to be essential for microglial cell migration. CX3CL1 is also up-regulated in the hippocampus during a brief temporal window following spatial learning, the purpose of which may be to regulate glutamate-mediated neurotransmission tone. This indicates a possible role for the chemokine in the protective plasticity process of synaptic scaling.

CX3CL1 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
QuetmolimabE-6011; KANAB-001Phase 2 ClinicalEisai Co Ltd
Arthritis, Rheumatoid; Cholangitis, Sclerosing; Crohn Disease
Details